Axzyb 5MG Tablet, containing the active ingredient Axitinib, is a targeted therapy primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. This medication works by inhibiting specific proteins that promote tumor growth and blood vessel formation, thereby slowing down the progression of cancer. Each tablet contains 5 mg of Axitinib, and it is typically available in a pack of 30 tablets. Axzyb is designed for patients who have previously undergone treatment with other therapies, making it a crucial option in the management of advanced RCC. The drug is taken orally, and its effectiveness is enhanced when used as part of a comprehensive cancer treatment plan, which may include surgery, radiation, or other medications. Understanding the composition and purpose of Axzyb is essential for patients and healthcare providers alike, as it plays a significant role in improving outcomes for those battling advanced kidney cancer.